Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.33
+0.38 (0.60%)
At close: Dec 5, 2025, 4:00 PM EST
64.25
+0.92 (1.45%)
After-hours: Dec 5, 2025, 7:55 PM EST
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Halozyme Therapeutics stock have an average target of 73.33, with a low estimate of 53 and a high estimate of 92. The average target predicts an increase of 15.79% from the current stock price of 63.33.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 3 | 3 | 3 |
| Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 3 | 3 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +42.11% | Nov 28, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $54 → $56 | Hold | Maintains | $54 → $56 | -11.57% | Nov 18, 2025 |
| Citizens | Citizens | Buy Maintains $91 → $92 | Buy | Maintains | $91 → $92 | +45.27% | Nov 4, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $63 → $65 | Hold | Maintains | $63 → $65 | +2.64% | Oct 27, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $80 → $79 | Buy | Maintains | $80 → $79 | +24.74% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
1.35B
from 1.02B
Increased by 32.47%
Revenue Next Year
1.67B
from 1.35B
Increased by 24.31%
EPS This Year
6.28
from 3.43
Increased by 83.08%
EPS Next Year
8.14
from 6.28
Increased by 29.55%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.4B | 1.8B | ||||
| Avg | 1.3B | 1.7B | ||||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 38.1% | 33.7% | ||||
| Avg | 32.5% | 24.3% | ||||
| Low | 26.0% | 14.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.63 | 8.93 | ||||
| Avg | 6.28 | 8.14 | ||||
| Low | 5.93 | 7.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 93.2% | 42.1% | ||||
| Avg | 83.1% | 29.6% | ||||
| Low | 72.9% | 12.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.